IMMUNOHISTOCHEMISTRY, CEA

The IHC – CEA (Carcinoembryonic Antigen) test is an immunohistochemistry-based diagnostic assay used to detect CEA protein expression in tissue samples. CEA is a glycoprotein involved in cell adhesion and is normally produced during fetal development. In adults, elevated CEA expression is commonly associated with several types of cancers, particularly adenocarcinomas.

This test is widely used in pathology to identify and classify tumors, especially those arising from the gastrointestinal tract, lungs, pancreas, and other epithelial tissues. CEA staining helps pathologists determine the origin of malignant cells and differentiate adenocarcinomas from other tumor types.

Benefits of the Test

• Helps diagnose adenocarcinomas
• Assists in determining tumor origin
• Supports differentiation of epithelial malignancies
• Improves tumor classification accuracy
• Helps guide oncology treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC CEA test when there is suspicion of adenocarcinoma or metastatic cancer of unknown origin. It is commonly used in:

• Diagnosis of colorectal adenocarcinoma
• Evaluation of gastrointestinal cancers
• Assessment of pancreatic and lung adenocarcinomas
• Investigation of metastatic tumors
• Oncology biopsy interpretation

CEA is frequently used alongside markers such as CK7, CK20, CDX2, MUC1, MUC2, and EMA to improve diagnostic accuracy and identify the primary site of cancer.

Preparation Before Test

No special preparation is required from the patient. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are needed
• Clinical history, imaging studies, and pathology findings may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected adenocarcinoma
• Individuals with gastrointestinal or lung tumors
• Cases of metastatic cancer requiring origin identification
• Patients undergoing tumor biopsy evaluation
• Oncology patients requiring immunohistochemistry profiling

The IHC CEA test is an important diagnostic tool in surgical pathology and oncology. By identifying CEA expression in tissue samples, it helps clinicians accurately diagnose adenocarcinomas, determine tumor origin, and develop effective treatment strategies.

Key Clinical Applications

CEA immunohistochemistry is particularly useful in evaluating:

• Colorectal adenocarcinoma
• Gastric adenocarcinoma
• Pancreatic adenocarcinoma
• Lung adenocarcinoma
• Metastatic epithelial malignancies
• Tumors with uncertain primary origin